CORCEPT THERAPEUTICS INC Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount
CORCEPT THERAPEUTICS INC (CORT) reported Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount of -$1.20 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-28.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationOtherReconcilingItems · last filed 2018-02-28
- CORCEPT THERAPEUTICS INC effective income tax rate reconciliation, other reconciling items, amount for fiscal 2017 was -$1.20M.
- CORCEPT THERAPEUTICS INC effective income tax rate reconciliation, other reconciling items, amount for fiscal 2016 was -$69.00K.
- CORCEPT THERAPEUTICS INC effective income tax rate reconciliation, other reconciling items, amount for fiscal 2015 was -$445.00K.
- CORCEPT THERAPEUTICS INC effective income tax rate reconciliation, other reconciling items, amount for fiscal 2014 was -$1.31M.
| Period end | Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount 12 month |
|---|---|
| 2017-12-31 | -$1.20M 10-K · filed 2018-02-28 |
| 2016-12-31 | -$69.00K 10-K · filed 2018-02-28 |
| 2015-12-31 | -$445.00K 10-K · filed 2018-02-28 |
| 2014-12-31 | -$1.31M 10-K · filed 2017-03-06 |
| 2013-12-31 | -$1.51M 10-K · filed 2016-03-10 |
| 2012-12-31 | -$2.19M 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |